Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes

Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes

<p><strong>Objectives</strong> The purpose of this study was to explore potential mediators of the effects of canagliflozin on heart failure in the CANVAS Program (CANagliflozin cardioVascular Assessment Study; NCT01032629 and CANagliflozin cardioVascular Assessment Study–Renal; NC...

Full description

Bibliographic Details
Main Authors:	Li, J, Woodward, M, Perkovic, V, Matthews, DR, al., E
Format:	Journal article
Published:	Elsevier 2019

Similar Items

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
by: Akira Sezai, et al.
Published: (2019-06-01)

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
by: Atsushi Tanaka, et al.
Published: (2020-08-01)

Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study
by: Ernesto Martín, et al.
Published: (2021-02-01)

Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-01-01)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-10-01)

De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
by: Luis M. Pérez-Belmonte, et al.
Published: (2021-05-01)

Diabetic Ketoacidosis in A Patient with Type 2 Diabetes On Canagliflozin and Dexamethasone
by: Lisa D. Alexander, MD, et al.
Published: (2017-01-01)

Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial
by: Atsushi Tanaka, et al.
Published: (2022-12-01)

Emerging treatments in type 2 diabetes: focus on canagliflozin
by: Rosiak M, et al.
Published: (2014-08-01)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
by: Shusuke Yagi, et al.
Published: (2017-10-01)

Canagliflozin: a novel treatment option for type 2 diabetes
by: Dietrich E, et al.
Published: (2013-11-01)

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats
by: Manal M.G. Mourad*, et al.
Published: (2023-07-01)

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
by: Akira Sezai, et al.
Published: (2022-07-01)

Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
by: Atsushi Tanaka, et al.
Published: (2022-08-01)

Patient profiling in diabetes and role of canagliflozin
by: Amblee A
Published: (2014-11-01)

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
by: Daisuke Matsutani, et al.
Published: (2018-05-01)

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
by: Skelley JW, et al.
Published: (2018-12-01)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
by: K M Prasanna Kumar, et al.
Published: (2016-01-01)

Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy plus /- oral agents in type 2 diabetes
by: Matthews, DR, et al.
Published: (2012)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
by: AnneMarie Nardolillo, et al.
Published: (2014-09-01)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
by: AnneMarie Nardolillo, et al.
Published: (2014-01-01)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
by: Sok Cin Tye, et al.
Published: (2022-09-01)

Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus
by: Hsiao-Huai Kuo, et al.
Published: (2023-12-01)

Canagliflozin combined with aerobic exercise protects against chronic heart failure in rats
by: Helin Sun, et al.
Published: (2024-03-01)

Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016-08-01)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014-01-01)

Risk of heart failure in type 2 diabetes
by: Coleman, R, et al.
Published: (2003)

Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
by: Kenya Kusunose, et al.
Published: (2021-09-01)

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus
by: Limin Wang, et al.
Published: (2023-10-01)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
by: Xingyun Hou, et al.
Published: (2019-05-01)

Candidemia Following Ureteric Stent Placement in a Patient With Type 2 Diabetes Treated With Canagliflozin
by: Rishi Raj, et al.
Published: (2019-01-01)

Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes mellitus
by: W.T. Garvey, et al.
Published: (2017-11-01)

Prolonged diabetic ketoacidosis associated with canagliflozin
by: Gordon Sloan, et al.
Published: (2018-06-01)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
by: Davies MJ, et al.
Published: (2017-01-01)

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
by: Manash P Baruah, et al.
Published: (2016-01-01)

The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review
by: Vikri Haikal, et al.
Published: (2024-01-01)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
by: Fleming JW, et al.
Published: (2015-06-01)

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
by: Messana JA, et al.
Published: (2017-02-01)

The role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolution
by: M. V. Shestakova, et al.
Published: (2023-11-01)